The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma

Trond Velde Bogsrud, Dimitrios Karantanis, Mark A. Nathan, Brian P. Mullan, Gregory A. Wiseman, Jan L. Kasperbauer, Carl C. Reading, Trine Björo, Ian D. Hay, Val J. Lowe

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Purpose: To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures: This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Results: Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. Conclusion: FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.

Original languageEnglish (US)
Pages (from-to)547-553
Number of pages7
JournalMolecular Imaging and Biology
Volume12
Issue number5
DOIs
StatePublished - Oct 1 2010

Keywords

  • 2-deoxy-2-[18F]fluoro-d-glucose
  • FDG
  • Medullary thyroid carcinoma
  • PET
  • PET/CT
  • Positron emission tomography

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma'. Together they form a unique fingerprint.

  • Cite this